Literature DB >> 33514595

Precision shielding for COVID-19: metrics of assessment and feasibility of deployment.

John P A Ioannidis1.   

Abstract

The ability to preferentially protect high-risk groups in COVID-19 is hotly debated. Here, the aim is to present simple metrics of such precision shielding of people at high risk of death after infection by SARS-CoV-2; demonstrate how they can estimated; and examine whether precision shielding was successfully achieved in the first COVID-19 wave. The shielding ratio, S, is defined as the ratio of prevalence of infection among people in a high-risk group versus among people in a low-risk group. The contrasted risk groups examined here are according to age (≥70 vs <70 years), and institutionalised (nursing home) setting. For age-related precision shielding, data were used from large seroprevalence studies with separate prevalence data for elderly versus non-elderly and with at least 1000 assessed people≥70 years old. For setting-related precision shielding, data were analysed from 10 countries where information was available on numbers of nursing home residents, proportion of nursing home residents among COVID-19 deaths and overall population infection fatality rate (IFR). Across 17 seroprevalence studies, the shielding ratio S for elderly versus non-elderly varied between 0.4 (substantial shielding) and 1.6 (substantial inverse protection, that is, low-risk people being protected more than high-risk people). Five studies in the USA all yielded S=0.4-0.8, consistent with some shielding being achieved, while two studies in China yielded S=1.5-1.6, consistent with inverse protection. Assuming 25% IFR among nursing home residents, S values for nursing home residents ranged from 0.07 to 3.1. The best shielding was seen in South Korea (S=0.07) and modest shielding was achieved in Israel, Slovenia, Germany and Denmark. No shielding was achieved in Hungary and Sweden. In Belgium (S=1.9), the UK (S=2.2) and Spain (S=3.1), nursing home residents were far more frequently infected than the rest of the population. In conclusion, the experience from the first wave of COVID-19 suggests that different locations and settings varied markedly in the extent to which they protected high-risk groups. Both effective precision shielding and detrimental inverse protection can happen in real-life circumstances. COVID-19 interventions should seek to achieve maximal precision shielding. © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  COVID-19

Year:  2021        PMID: 33514595     DOI: 10.1136/bmjgh-2020-004614

Source DB:  PubMed          Journal:  BMJ Glob Health        ISSN: 2059-7908


  6 in total

1.  [COVID-19 in care homes: equity will be needed to avoid new catastrophes].

Authors:  María Victoria Zunzunegui
Journal:  Gac Sanit       Date:  2021-07-21       Impact factor: 2.139

2.  'We thank you for your sacrifice': Clinical vulnerability, shielding and biosociality in the UK's Covid-19 response.

Authors:  Clare Herrick
Journal:  Biosocieties       Date:  2022-01-22

3.  Infection fatality rate of COVID-19 in community-dwelling elderly populations.

Authors:  Cathrine Axfors; John P A Ioannidis
Journal:  Eur J Epidemiol       Date:  2022-03-20       Impact factor: 12.434

Review 4.  The SARS-CoV-2 Pandemic in High Income Countries Such as Canada: A Better Way Forward Without Lockdowns.

Authors:  Ari R Joffe; David Redman
Journal:  Front Public Health       Date:  2021-11-22

5.  COVID-19 models and expectations - Learning from the pandemic.

Authors:  John P A Ioannidis; Stephen H Powis
Journal:  Adv Biol Regul       Date:  2022-10-08

6.  Harnessing Artificial Intelligence to assess the impact of nonpharmaceutical interventions on the second wave of the Coronavirus Disease 2019 pandemic across the world.

Authors:  Sile Tao; Nicola Luigi Bragazzi; Jianhong Wu; Bruce Mellado; Jude Dzevela Kong
Journal:  Sci Rep       Date:  2022-01-18       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.